Abstract Library

#2853 Succinate Dehydrogenase B (SDHB) Immunohistochemical Expression in Pancreatic Neuroendocrine Tumours and Correlation with Somatostatin Receptor Immunohistochemistry

Introduction: The established category of succinate dehydrogenase (SDH) deficient neoplasms includes several endocrine tumours with recent evidence that pancreatic neuroendocrine tumours (PNETs) could be included in this tumour group. The SDH complex is composed of four subunits (A-D) but loss of immunohistochemical (IHC) expression for SDHB indicates bi-allelic inactivation of any SDH component and is used as a marker for syndromic disease.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Swan N

Authors: Swan N, Nadeem N, Crowley R,

Keywords: succinate dehydrogenase, pancreatic neuroendocrine tumor, somatostatin receptor, immunohistochemistry,

#942 Ileal Neuroendocrine Well-Differentiated Tumors: Prognostic factors with Focus on Loss of Succinate Dehydrogenase (SDHB) Expression

Introduction: Ileal Neuroendocrine Well-Differentiated Tumors (INWDT) are the most common neuroendocrine neoplasms in the gastrointestinal tract. Gene mutations of SDH complex drive pathogenesis of cancer cells through their role in angiogenesis and cell proliferation.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: MILIONE M

Authors: Milione M, Gasparini P, Pusceddu S, Coppa J, Pellegrinelli A,

Keywords: ileum, neuroendocrine, SDHB, Ki-67, mitosis,

#880 Novel Succinate Dehydrogenase Subunit B Intronic Mutation in an Australian Kindred with Variable Clinical and Imaging Phenotype Necessitating Different Treatment Modalities Including 131-I MIBG and 177-Lutetium DOTATATE

Introduction: SDH B mutation has variable functional imaging phenotype challenging in terms of diagnosis, treatment modalities and follow-up.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Lee K, Conway L, Burge M, Wyld D, Macfarlane D,

Keywords: SDHB, Paraganglioma,

#838 Succinate Dehydrogenase Subunit B (SDHB) Immunohistochemistry Should Not Replace Clinical Genetic Testing for SDHx Mutations in Patients with Pheochromocytoma and Paraganglioma

Introduction: Mutations in any of the subunits of the succinate dehydrogenase (SDH) complex predispose to PCC/PGL. Knowing the germline mutation is important for surveillance for recurrence, metastatic disease or more primary tumors and for screening affected family members. Expression of SDHB protein by immunohistochemistry (IHC) has been proposed as a surrogate marker for SDHx mutation status, with absent or decreased expression of SDHB suggesting the presence of a germline SDHB mutation or disruption of the SDH complex by mutation in another subunit.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Fishbein L, Bennett B, Merrill S, Cohen D, LiVolsi V,

Keywords: Pheo, succinate dehydrogenase,

#645 Loss of Succinate Dehydrogenase (SDHB) in Midgut Carcinoids as Prognostic Factor: A New Marker of Personalized Cancer Medicine in Neuroendocrine Tumors?

Introduction: Gene mutations of the succinate dehydrogenase (SDH) complex are involved in the pathogenesis of cancer cells and play a pivotal role in angiogenesis and cell proliferation. The immunoistochemical (IHC) loss of SDHB is a marker of malignancy in pheocromocytomas and paragangliomas.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: MILIONE M

Authors: Milione M, Pusceddu S, Buzzoni R, Damato A, Coppa J,

Keywords: midgut, SDHB,